Tag: Zetia
Hypercholesterolemia Treatment Falls Short of Guidelines
In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines
Stratification Tool IDs Who Will Benefit From Adding Ezetimibe
Tool identifies who will derive additional benefit from addition of ezetimibe to statin therapy after ACS
Ezetimibe Plus Rosuvastatin Bests Rosuvastatin Alone
Combo tx linked to significant reductions in LDL, total cholesterol, triglycerides versus rosuvastatin
Nutraceuticals Alone or With Ezetimibe Aid in Dyslipidemia
Improvement in lipid profile for nutraceuticals alone or in combo for statin-intolerant patients
